Nehme, MayssamHund Georgiadis, MargretCorral Beamonte, Esther DelBridevaux, Pierre OlivierHoepner, RobertPenner, Iris KatharinaStrobel, JoanaFretz, GregoryBoada Rovira, MercèGuisado Vasco, Pabloet al.2026-07-222026-07-222026Nehme, M., Hund-Georgiadis, M., Corral Beamonte, E. D., Bridevaux, P.-O., Hoepner, R., Penner, I.-K., Strobel, J., Fretz, G., Rovira, M. B., Puchades, F., Landi, F., Vasco, P. G., Guaraldi, G., Cordero, F. M., Sebastianelli, L., Sarmati, L., Berthuy, N., Wojcik, J., Keddad, K., … Guessous, I. (2026). Temelimab versus placebo in patients with post-COVID condition. Brain, Behavior, and Immunity, 138, 106892. https://doi.org/10.1016/j.bbi.2026.1068920889-15911090-2139https://hdl.handle.net/11268/17301More than 400 million individuals are estimated to have been affected by post-COVID condition or long COVID. This condition can lead to significantly decreased quality of life and increased individual and societal costs. Temelimab, a monoclonal IgG4 backbone antibody targeting HERV-W ENV, may be a potential treatment for post-COVID. In adults with persistent symptoms due to post-COVID condition, the use of Temelimab did not show improvement in fatigue compared to placebo.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Medicina, Salud y DeportesSíndrome Post Agudo de COVID-19Anticuerpos MonoclonalesInmunoterapiajournal article10.1016/j.bbi.2026.106892open accessCiencias médicasInmunologíaFarmacologíaGoal 3: Ensure healthy lives and promote well-being for all at all agesGoal 9: Build resilient infrastructure, promote sustainable industrialization and foster innovationGoal 17: Partnerships